News
Explore Moderna's growth potential with FDA-approved respiratory vaccines, strong cash reserves, and a robust pipeline.
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
StockStory.org on MSN17h
Why Moderna (MRNA) Stock Is Falling TodayShares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...
The FDA has approved Moderna’s next-generation COVID-19 vaccine for people older than 65. REUTERS “The FDA approval of our third product, mNEXSPIKE, ...
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results